AEGIS-II: Apo A-I Infusions Did Not Reduce 90-Day MACE but Trended Towards Reduction in CV Death and MI
Key Points: Post-MI adverse cardiovascular events remain high despite robust evidence-based antiplatelet, statin, and anticoagulant therapy. Cholesterol efflux is... Read more.
Self-Expanding Evolut Valve non-inferior to Balloon-Expandable SAPIEN Valve in Severe Aortic Stenosis and Small Aortic Annuli
Key Points: The SMART trial is the first randomized non-inferiority trial to test a head-to-head comparison between the Medtronic Evolut valve (Evolut PRO/PRO+/FX)... Read more.
A single SC dose of Zilebesiran reduced systolic blood pressure in uncontrolled hypertension: KARDIA-2
Key Points: Zilebesiran is a subcutaneous injectable that targets hepatic angiotensinogen (AGT) synthesis by RNA interference. The KARDIA-1 trial showed that subcutaneous... Read more.
BE ACTIVE RCT: Financial incentive and gamification strategies borrowed from behavioral economics increased physical activity among adults at elevated ASCVD risk
Key Points: The majority of US adults at elevated risk for ASCVD do not engage in the recommended amount of daily exercise. Behavioral economic strategies to incentivize... Read more.
STEP-HFpEF DM TRIAL: Semaglutide improves HF-related symptoms and results in greater weight loss among patients with obesity-related HFpEF and type 2 DM
Key Points: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown to reduce body weight and improve HF-related symptoms among individuals... Read more.
Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome (TELE-ACS)
Key Points: TELE-ACS evaluates the use of telemedicine strategies to reduce hospital readmission rates in patients with a recent history of acute coronary syndrome ... Read more.
An “Inclisiran First” Strategy Shows Greater LDL-C Lowering Compared With Usual Care In Patients With ASCVD: The VICTORION-INITIATE Randomized Trial
Key Points: Most patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve sufficiently reduced low-density lipoprotein cholesterol (LDL-C) levels... Read more.
EMPACT-MI: Empagliflozin did not meet primary endpoint but significantly reduced HF hospitalizations
Key Points: Incident heart failure remains common among patients who experience acute myocardial infarction despite recent advances in medical therapy and revascularization... Read more.
Self-monitoring and physician-optimized antihypertensive titration post-partum decreases BP during the first 9 months
Key Points: Up to 1 in 10 women experience a hypertensive disorder of pregnancy, which is associated with long-term cardiovascular disease. However there are no... Read more.
Novel RNA interference therapeutic Zilebesiran results in dose-dependent sustained BP reduction
Key Points: Uncontrolled hypertension is a major public health concern, and this condition is often primarily driven by the renin-angiotensin (RAAS) pathway. A new... Read more.